Crinecerfont: First Approval
Related Experiment Video
Updated: May 11, 2026

A Craniotomy Surgery Procedure for Chronic Brain Imaging
Published on: February 15, 2008
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Crinecerfont (CRENESSITY™) is a corticotropin releasing factor type 1 (CRF1) receptor antagonist developed by Neurocrine Biosciences for the treatment of classic congenital adrenal hyperplasia (CAH) in adult and paediatric patients. In patients with classic CAH, circulating levels of adrenocorticotropic hormone (ACTH), androstenedione and 17-hydroxyprogesterone are elevated, which traditionally has required supraphysiologic doses of glucocorticoids to manage. As a CRF1 receptor antagonist, crinecerfont acts by reducing systemic ACTH secretion to subsequently decrease elevated levels of steroid precursors and adrenal androgens, thereby reducing the dosage of glucocorticoids required to manage androgen levels in patients. This article summarizes the milestones in the development of crinecerfont leading to this first approval as an adjunctive treatment to glucocorticoid replacement to control androgens in adults and paediatric patients aged ≥ 4 years with classic CAH.
Related Concept Videos
Review and Preview
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Mechanism
Review and Preview
Percentiles are a type of fractile that partition data into...
First Pass Effect
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
First-Order Circuits
One common example of a first-order circuit is the RC (resistor-capacitor) circuit. These circuits are used in relaxation oscillators such as neon lamp oscillator circuits. When voltage is...
First Impression

